TITLE

FDA approves Amgen's drug for chronic kidney disease

PUB. DATE
April 2004
SOURCE
PharmaWatch: Biotechnology;April 2004, Vol. 3 Issue 4, p13
SOURCE TYPE
Market Research Report
DOC. TYPE
Article
ABSTRACT
Reports on the approval of the U.S. Food and Drug Administration to Amgen Inc.'s Sensipar drug targeting chronic kidney disease. Classification of Sensipar; Safety and efficacy of the drug; Response of patients taking Sensipar.
ACCESSION #
13853983

 

Related Articles

  • FDA grants priority review to Gilead's HIV co-formulation.  // PharmaWatch: Biotechnology;July 2004, Vol. 3 Issue 7, p13 

    Reports on the approval of the U.S. Food and Drug Administration to Gilead Sciences Inc.'s New Drug Application for the fixed dose co-formulation of the anti-HIV medications Viread and Emtriva. Terms under the priority review; Designation granted to drugs; Administration of the proposed...

  • ImClone wins FDA approval for Erbitux.  // PharmaWatch: Biotechnology;April 2004, Vol. 3 Issue 4, p13 

    Reports on the approval of the U.S. Food and Drug Administration (FDA) to ImClone Systems Inc.'s Erbitux designated to treat advanced colorectal cancer. Impact of the approval of the FDA on the operation of the company; Evidence showing the safety and efficacy of Erbitux; Response of patients...

  • Denosumab Receives Conditional Approval from FDA Expert Panel. Elliott, William T. // Neurology Alert;Oct2009 Pharmacology Watch, p2 

    The article reports that a condition approval has been given to Denosumab, a new human monoclonal antibody, by a Food and Drug Administration (FDA) Expert Panel. The agency is testing the drug for treatment of osteoporosis in men and women. The drug would be branded as Proliaâ„¢ by Amgen...

  • Amgen's Moves Praised As Firm Faces Challenges.  // Bioworld Week;8/20/2007, Vol. 15 Issue 34, p5 

    The article reports that the move of Amgen Inc. to meet with the U.S. Food and Drug Administration (FDA) on erythropoietin stimulating agents (ESA) has been praised. It is stated that Amgen's move for the utilization of its ESA has been admirable since there is a possibility that the federal...

  • Impax receives final FDA approval for generic version of Sinemet.  // PharmaWatch: CNS;June 2004, Vol. 3 Issue 6, p12 

    Reports on the approval of the U.S. Food and Drug Administration (FDA) to Impax Laboratories Inc.'s Abbreviated New Drug Application for Carbidopa/Levodopa designated for the treatment of Parkinson disease. Plan of the company for the marketing of the drug; Comments from Larry Hsu, president of...

  • Genentech: first-line colorectal cancer treatment approved.  // PharmaWatch: Biotechnology;April 2004, Vol. 3 Issue 4, p9 

    Reports on the approval of the U.S. Food and Drug Administration to Genentech Inc.'s Avastin in combination with 5FU-based regimen for the treatment of colorectal cancer. Basis for the approval of Avastin; Comparison between Avastin and leucovorin in terms of survival of cancer patients;...

  • Genentech's Avastin gains FDA approval.  // PharmaWatch: Biotechnology;April 2004, Vol. 3 Issue 4, p13 

    Reports on the approval of the U.S. Food and Drug Administration to Genentech Inc.'s Avastin targeting metastatic cancer of the colon or rectum. Safety and efficacy of Avastin; Response of patients treated with Avastin; Recommendation of the FDA for Avastin as first line treatment option for...

  • FDA Approvals In June.  // BioWorld Insight;7/15/2013, Vol. 21 Issue 29, p7 

    A table is presented which lists the drugs approved by the U.S. Food and Drug Administration and their company including Xgeva from Amgen Inc., Revlimid from Celgene Corp. and Vibativ from Theravance Inc. and also offers information on their theurapeutic effect.

  • AMGEN. Investor's Business Daily // Investors Business Daily;4/16/2015, pA02 

    The article reports on the approval of the U.S. Food and Drug Administration (FDA) for Corlanor drug manufactured by biopharmaceutical company Amgen Inc. on top of standard beta blockers for chronic heart failure patients.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics